MedTrace Logo

Study on the Use of Interferon Gamma (Ingaron) Injections in Patients With Drug-resistant Pulmonary Tuberculosis

NCT05359315 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 84

Last updated 2022-06-01

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and tolerability of the complex therapy of drug-resistant respiratory tuberculosis using the drug Ingaron, a lyophilisate for the preparation of a solution for injection for intramuscular or subcutaneous administration of 500,000 IU.

Conditions

  • Pulmonary Tuberculosis

Interventions

DRUG

Interferon-Gamma

received by microbiological synthesis; specific antiviral activity on cells is 2x10\*7 Units per mg of protein

Sponsors & Collaborators

  • SPP Pharmaclon Ltd.

    lead INDUSTRY

Principal Investigators

  • Anatoly I Saulin, Master · SPP Pharmaclon Ltd.

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-15
Primary Completion
2022-08-01
Completion
2023-05-01

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05359315 on ClinicalTrials.gov